A guanidine-rich regulatory oligodeoxynucleotide improves type-2 diabetes in obese mice by blocking T-cell differentiation

EMBO Mol Med. 2012 Oct;4(10):1112-25. doi: 10.1002/emmm.201201272.

Abstract

T lymphocytes exhibit pro-inflammatory or anti-inflammatory activities in obesity and diabetes, depending on their subtypes. Guanidine-rich immunosuppressive oligodeoxynucleotides (ODNs) effectively control Th1/Th2-cell counterbalance. This study reveals a non-toxic regulatory ODN (ODNR01) that inhibits Th1- and Th17-cell polarization by binding to STAT1/3/4 and blocking their phosphorylation without affecting Th2 and regulatory T cells. ODNR01 improves glucose tolerance and insulin sensitivity in both diet-induced obese (DIO) and genetically generated obese (ob/ob) mice. Mechanistic studies show that ODNR01 suppresses Th1- and Th17-cell differentiation in white adipose tissue, thereby reducing macrophage accumulation and M1 macrophage inflammatory molecule expression without affecting M2 macrophages. While ODNR01 shows no effect on diabetes in lymphocyte-free Rag1-deficient DIO mice, it enhances glucose tolerance and insulin sensitivity in CD4(+) T-cell-reconstituted Rag1-deficient DIO mice, suggesting its beneficial effect on insulin resistance is T-cell-dependent. Therefore, regulatory ODNR01 reduces obesity-associated insulin resistance through modulation of T-cell differentiation.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Cell Differentiation / drug effects*
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Disease Models, Animal
  • Mice
  • Mice, Inbred BALB C
  • Mice, Inbred C57BL
  • Mice, Obese*
  • Oligodeoxyribonucleotides / administration & dosage*
  • Phosphorylation / drug effects
  • STAT1 Transcription Factor / antagonists & inhibitors
  • STAT3 Transcription Factor / antagonists & inhibitors
  • STAT4 Transcription Factor / antagonists & inhibitors
  • Th1 Cells / drug effects*
  • Th17 Cells / drug effects*
  • Treatment Outcome

Substances

  • Oligodeoxyribonucleotides
  • STAT1 Transcription Factor
  • STAT3 Transcription Factor
  • STAT4 Transcription Factor
  • Stat1 protein, mouse
  • Stat3 protein, mouse
  • Stat4 protein, mouse